The global outbreak of COVID-19 has led to a critical need for effective therapeutic strategies. Among these, early administration of antiviral agents such as remdesivir and molnupiravir has shown potential to reduce disease severity and improve clinical outcomes. This study investigates the clinical impact of initiating antiviral therapy during the early phase of SARS-CoV-2 infection, focusing on hospitalization rates, ICU admissions, and mortality.

COVID-19, SARS-CoV-2, antiviral therapy, remdesivir, early treatment, clinical outcomes

Gottlieb, R. L., Vaca, C. E., Paredes, R., et al. (2022). Early remdesivir to prevent progression to severe COVID-19 in outpatients. New England Journal of Medicine, 386(4), 305–315. https://doi.org/10.1056/NEJMoa2116846

Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., et al. (2022). Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. New England Journal of Medicine, 386(6), 509–520. https://doi.org/10.1056/NEJMoa2116044

Hammond, J., Leister-Tebbe, H., Gardner, A., et al. (2022). Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine, 386(15), 1397–1408. https://doi.org/10.1056/NEJMoa2118542

WHO Solidarity Trial Consortium. (2022). Remdesivir and three other drugs for hospitalized patients with COVID-19: Final results of the WHO Solidarity randomized trial and updated meta-analyses. The Lancet, 399(10339), 1941–1953. https://doi.org/10.1016/S0140-6736(22)00519-0